Neovasc Completes $4.72 Million Private Placement
TSX Venture Exchange: NVC
–Will Fund New Initiative to Treat Mitral Valve Disease and Completion of COSIRA Trial Designed to Support Marketing
Approval of Neovasc Reducer(TM) for Treatment of Refractory Angina–
VANCOUVER, Aug. 17, 2011 /PRNewswire/ – Neovasc Inc. (TSXV: NVC) today
announced that it has completed a previously announced non-brokered
private placement of 4,720,500 equity units at the price of $1.00 per
unit for aggregate gross proceeds of approximately $4,720,500.
Reflecting strong demand, the total amount of the financing was
increased from the previously announced maximum of $4 million. Proceeds
of the offering will be used to complete the COSIRA clinical trial,
which is designed to provide randomized, controlled safety and efficacy
data for the Neovasc Reducer(TM), an innovative implantable product for
treating refractory angina, as well as to advance Neovasc’s Tiara(TM)
project to develop a novel transcatheter medical device to treat mitral
valve heart disease.
Each unit consists of one common share of Neovasc stock and one-half of
one common share purchase warrant of Neovasc stock. Each whole warrant
entitles the holder thereof to purchase one common share of Neovasc
stock at the exercise price of $1.25 per share for a period of two
years after the closing date of the offering. The securities issued are
subject to a four-month hold period from the date of issuance and the
placement has been approved by the TSX Venture Exchange.
Participants in the placement included OPKO Health Inc. (NYSE Amex: OPK)
which invested $2 million and Gagnon Securities LLC, whose members
invested $1.42 million. Company directors and officers purchased 95,000
of the equity units issued.
Alexei Marko, CEO of Neovasc commented, “We are encouraged by the strong
support we received from new investors in this oversubscribed
financing. Completion of this placement provides Neovasc with the
necessary funding to significantly advance our pipeline projects that
we believe have substantial clinical and commercial potential.”
About Neovasc Inc.
Neovasc is a specialty vascular device company that develops,
manufactures and markets medical devices for the rapidly growing
vascular marketplace. The company’s current products include the
Neovasc Reducer(TM), a novel product in development to treat refractory
angina and Tiara(TM), a product being developed to treat mitral valve
disease as well as a line of advanced biological tissue technologies
that are used to enhance surgical outcomes and as key components in a
variety of third party medical products such as transcatheter heart
valves. For more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
“anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,”
and “will” and words of similar import, constitute “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions, both
nationally and in the regions in which the Company operates; history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired
businesses, technology changes; competition; changes in business
strategy or development plans; the ability to attract and retain
qualified personnel; existing governmental regulations and changes in,
or the failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors referenced
in the Company’s filings with Canadian securities regulators. Although
the Company believes that expectations conveyed by the forward-looking
statements are reasonable based on the information available to it on
the date such statements were made, no assurances can be given as to
the future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as otherwise
required by applicable law.
SOURCE Neovasc Inc.